[{"address1": "2100 Powell Street", "address2": "Suite 720", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 848 5100", "fax": "510 848 1327", "website": "https://www.dynavax.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.", "fullTimeEmployees": 408, "companyOfficers": [{"maxAge": 1, "name": "Mr. David F. Novack", "age": 61, "title": "President & COO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1013581, "exercisedValue": 1505490, "unexercisedValue": 4049009}, {"maxAge": 1, "name": "Mr. Justin  Burgess", "title": "Chief Accounting Officer & Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff P. Coon", "age": 60, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul  Cox", "title": "VP of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John L. Slebir", "age": 57, "title": "Senior VP & General Counsel", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donn  Casale", "title": "Senior VP & Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dong  Yu", "title": "Senior Vice President of Vaccine Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Frings", "title": "VP, Site Head & MD for Dynavax GmbH", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd  Lopeman", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Riccardo  Manetti", "title": "Senior Vice President of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 3, "compensationRisk": 2, "shareHolderRightsRisk": 7, "overallRisk": 4, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.86, "open": 10.86, "dayLow": 10.745, "dayHigh": 10.86, "regularMarketPreviousClose": 10.86, "regularMarketOpen": 10.86, "regularMarketDayLow": 10.745, "regularMarketDayHigh": 10.86, "beta": 1.372, "trailingPE": 83.46155, "forwardPE": 29.324326, "volume": 1381402, "regularMarketVolume": 1381402, "averageVolume": 2183861, "averageVolume10days": 1913500, "averageDailyVolume10Day": 1913500, "bid": 9.2, "ask": 10.87, "bidSize": 100, "askSize": 500, "marketCap": 1421827456, "fiftyTwoWeekLow": 9.74, "fiftyTwoWeekHigh": 15.15, "priceToSalesTrailing12Months": 5.6942797, "fiftyDayAverage": 11.022, "twoHundredDayAverage": 12.22105, "currency": "USD", "enterpriseValue": 942811008, "profitMargins": 0.06879, "floatShares": 119681525, "sharesOutstanding": 131044000, "sharesShort": 18925087, "sharesShortPriorMonth": 17211590, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1444, "heldPercentInsiders": 0.00336, "heldPercentInstitutions": 1.0248001, "shortRatio": 8.54, "shortPercentOfFloat": 0.17639999, "bookValue": 4.908, "priceToBook": 2.2106764, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 2.319, "netIncomeToCommon": 17177000, "trailingEps": 0.13, "forwardEps": 0.37, "lastSplitFactor": "1:10", "lastSplitDate": 1415577600, "enterpriseToRevenue": 3.776, "enterpriseToEbitda": -119.783, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DVAX", "underlyingSymbol": "DVAX", "shortName": "Dynavax Technologies Corporatio", "longName": "Dynavax Technologies Corporation", "firstTradeDateEpochUtc": 1077201000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1098d91b-0224-393f-80a2-54d47c7c6e9b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.85, "targetHighPrice": 29.0, "targetLowPrice": 15.0, "targetMeanPrice": 24.5, "targetMedianPrice": 27.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 735612032, "totalCashPerShare": 5.613, "ebitda": -7871000, "totalDebt": 255280992, "quickRatio": 12.874, "currentRatio": 14.182, "totalRevenue": 249694000, "debtToEquity": 39.711, "revenuePerShare": 1.923, "returnOnAssets": -0.00791, "returnOnEquity": 0.02816, "freeCashflow": 24805624, "operatingCashflow": 38929000, "earningsGrowth": 2.072, "revenueGrowth": 0.225, "grossMargins": 0.60432, "ebitdaMargins": -0.031519998, "operatingMargins": 0.10032, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]